2021
Survival of Patients With Mild Secondary Mitral Regurgitation With and Without Mild Tricuspid Regurgitation
Mori M, Weininger G, Agarwal R, Shang M, Amabile A, Kahler-Quesada A, Yousef S, Pichert M, Vallabhajosyula P, Zhang Y, Sugeng L, Geirsson A. Survival of Patients With Mild Secondary Mitral Regurgitation With and Without Mild Tricuspid Regurgitation. Canadian Journal Of Cardiology 2021, 37: 1513-1521. PMID: 34119634, DOI: 10.1016/j.cjca.2021.06.005.Peer-Reviewed Original ResearchConceptsMild secondary mitral regurgitationLeft ventricular ejection fractionSecondary mitral regurgitationMild tricuspid regurgitationNormal left ventricular ejection fractionTricuspid regurgitationHazard of deathGroup 1Valvular abnormalitiesMitral regurgitationGroup 2Mean age 61 yearsGroup 4Cox proportional hazards modelGroup 1 patientsGroup 2 patientsGroup 3 patientsGroup 4 patientsAge 61 yearsRetrospective cohort studySurvival of patientsSubgroup of patientsProportional hazards modelCohort studyHealth care network57884 Fast strain-encoded cardiac magnetic resonance detects immune checkpoint inhibitor associated cardiotoxicity
Cuomo J, Ragheb E, Feher A, Kwan J, Huber S, Mojibian H, Peters D, Sinusas A, Baldassarre L. 57884 Fast strain-encoded cardiac magnetic resonance detects immune checkpoint inhibitor associated cardiotoxicity. Journal Of Clinical And Translational Science 2021, 5: 141-142. PMCID: PMC8827987, DOI: 10.1017/cts.2021.761.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsVentricular ejection fractionLV strainCardiotoxicity groupCheckpoint inhibitorsEjection fractionProspective studyCardiac functionNormal left ventricular ejection fractionLeft ventricular ejection fractionCardiac magnetic resonance imagingCardiac magnetic resonance imaging techniquesGlobal longitudinal LV strainAbnormal troponin valuesEvidence of cardiotoxicityProportion of myocardiumLarge prospective studiesLongitudinal LV strainStudy of patientsSteady-state free precession cine imagesAbnormal cardiac functionCircumferential LV strainT2-weighted imagingMagnetic resonance imagingDysfunctional segments
2016
Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link?
Peña M, Dunning A, Schulte PJ, Durheim MT, Kussin P, Checkley W, Velazquez EJ. Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link? Respiratory Medicine 2016, 121: 4-12. PMID: 27888991, DOI: 10.1016/j.rmed.2016.10.009.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionAdverse cardiovascular eventsPulmonary functionCause mortalityCardiovascular eventsCardiac hospitalizationCardiac functionDecreased LVEFNormal left ventricular ejection fractionSingle tertiary care medical centerTertiary care medical centerCox proportional hazards modelLeft heart remodelingRight heart dysfunctionAdverse cardiovascular outcomesRight ventricular functionTertiary care centerVentricular ejection fractionVentricular internal dimensionLeft heart structuresLeft heart sizeProportional hazards modelMultivariable linear regressionDecreased FVCCardiovascular outcomes
2012
Left Ventricular Ejection Fraction and Left Ventricular End‐Diastolic Volume in Patients With Diastolic Dysfunction
Jovin IS, Ebisu K, Liu Y, Finta LA, Oprea AD, Brandt CA, Dziura J, Wackers FJ. Left Ventricular Ejection Fraction and Left Ventricular End‐Diastolic Volume in Patients With Diastolic Dysfunction. Congestive Heart Failure 2012, 19: 130-134. PMID: 23241105, DOI: 10.1111/chf.12013.Peer-Reviewed Original ResearchConceptsLVEF of patientsLeft ventricular ejection fractionLower peak filling ratePeak filling rateEnd-diastolic volumeNormal peak filling ratesEquilibrium radionuclide angiocardiographyVentricular ejection fractionDiastolic dysfunctionAsymptomatic patientsEjection fractionLow left ventricular ejection fractionNormal left ventricular ejection fractionVentricular end-diastolic volumeMild systolic dysfunctionNormal systolic functionEDV indexSystolic dysfunctionSystolic functionRadionuclide angiocardiographyPatientsDysfunctionRepeat scansFilling rateAngiocardiography
2003
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Journal Of Clinical Oncology 2003, 21: 2889-95. PMID: 12885806, DOI: 10.1200/jco.2003.02.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlgorithmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsDisease ProgressionFemaleHeart DiseasesHumansInfusions, IntravenousMiddle AgedPredictive Value of TestsReceptor, ErbB-2ROC CurveSurvival AnalysisTrastuzumabTreatment OutcomeVinblastineVinorelbineConceptsLeft ventricular ejection fractionMetastatic breast cancerHER2-positive metastatic breast cancerBreast cancerHER2 extracellular domainResponse rateEjection fractionTumor markersNormal left ventricular ejection fractionMulticenter phase II studyMulticenter phase II trialPositive advanced breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Prior adjuvant chemotherapySafety of trastuzumabFirst-line chemotherapyPhase II studySymptomatic heart failureAdvanced breast cancerBaseline ejection fractionFirst-line therapyFirst-line treatmentPhase II trialTrastuzumab-based therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply